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Physiological and pharmacokinetic effects of oral
1,3-dimethylamylamine administration in men
Brian K Schilling1*, Kelley G Hammond1, Richard J Bloomer1, Chaela S Presley2 and Charles R Yates2
Abstract
Background: 1,3-dimethylamylamine (DMAA) has been a component of dietary supplements and is also used
within "party pills," often in conjunction with alcohol and other drugs. Ingestion of higher than recommended
doses results in untoward effects including cerebral hemorrhage. To our knowledge, no studies have been
conducted to determine both the pharmacokinetic profile and physiologic responses of DMAA.
Methods: Eight men reported to the lab in the morning following an overnight fast and received a single 25 mg
oral dose of DMAA. Blood samples were collected before and through 24 hours post-DMAA ingestion and analyzed
for plasma DMAA concentration using high-performance liquid chromatography–mass spectrometry. Resting heart
rate, blood pressure, and body temperature was also measured.
Results: One subject was excluded from the data analysis due to abnormal DMAA levels. Analysis of the remaining
seven participants showed DMAA had an oral clearance of 20.02 ± 5 L∙hr-1, an oral volume of distribution of 236 ±
38 L, and terminal half-life of 8.45 ± 1.9 hr. Lag time, the delay in appearance of DMAA in the circulation following
extravascular administration, varied among participants but averaged approximately 8 minutes (0.14 ± 0.13 hr). The
peak DMAA concentration for all subjects was observed within 3–5 hours following ingestion and was very similar
across subjects, with a mean of ~70 ng∙mL-1. Heart rate, blood pressure, and body temperature were largely
unaffected by DMAA treatment.
Conclusions: These are the first data to characterize the oral pharmacokinetic profile of DMAA. These findings
indicate a consistent pattern of increase across subjects with regards to peak DMAA concentration, with peak
values approximately 15–30 times lower than those reported in case studies linking DMAA intake with adverse
events. Finally, a single 25 mg dose of DMAA does not meaningfully impact resting heart rate, blood pressure, or
body temperature.
Trial registration: NCT01765933
Keywords: 1,3-dimethylamylamine, Pharmacokinetics, Dietary supplements
Background
The stimulant 1,3-dimethylamylamine (DMAA; also known
as methylhexaneamine) had been a component of many
dietary supplements in the United States until the Food
and Drug Administration warned retailers that DMAA did
not have ample evidence of safety [1]. Little is known about
the effects of oral administration of this compound in
humans, but animal studies have indicated that the
LD50 is 39 mg∙kg
-1 for intravenous [2] and 185 mg∙kg-1
for intraperitoneal [3] administration. Dietary supple-
ments containing DMAA were once widely available,
with an estimated 440,000,000 servings of such supple-
ments sold in recent years [4]. These doses are primar-
ily as a component of “pre-workout” supplements
marketed at those who exercise. The safety of this sim-
ple aliphatic amine has been called into question re-
cently, partially based on case reports documented in
New Zealand suggesting adverse outcomes following
oral DMAA ingestion [5,6]. In these case studies, which
cite cerebral hemorrhage following DMAA ingestion,
individuals reported ingesting a single dose of DMAA
(for its stimulant properties), often in conjunction with
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caffeine and alcohol [5,6]. Contrary to these case stud-
ies, several prospective investigations to date using
recommended doses have not shown any untoward side
effects [7-12]. Despite this, DMAA has been banned in
many countries, including the United States. The pur-
pose of this study was to characterize the plasma con-
centration profile and associated physiological effects
following a single 25 mg oral dose of DMAA.
Previously, Gee and coworkers [6] reported a patient
that purportedly ingested two “tablets” containing DMAA
(later confirmed by analysis to contain 278 mg of DMAA
per “capsule”: total dosage = 556 mg), along with 150 mg
of caffeine and one can of beer. In a subsequent report
[5], biochemical analysis of blood samples obtained from
patients ingesting a 12.5 and 132 mg dose of DMAA indi-
cated plasma DMAA concentrations of 760 ng∙mL-1
(17 hours post-ingestion) and 1090 ng∙mL-1(1.66 hours
post-ingestion). A third patient was noted to have a
plasma DMAA concentration of 2310 ng∙mL-1 (2 hours
post-ingestion); however, no information was provided re-
garding the ingested dosage of DMAA. As indicated in
these papers, it should be noted that other chemicals may
have been taken along with the DMAA-containing prod-
ucts (e.g., alcohol, caffeine, phenethylamine, and cannabis).
As mentioned previously, DMAA is often ingested
with caffeine for a proposed combined effect leading to
greater arousal than either alone. Four studies are avail-
able that used this combination in a placebo-controlled
design, and the health implications of DMAA in these
studies has been unremarkable. In varying concentra-
tions of caffeine and DMAA, there appears to be no
effect on heart rate [8], while DMAA affected blood
pressure and the rate-pressure product in a dose-
dependent manner. These changes were not related to
changes in norepinephrine or epinephrine, and caffeine/
DMAA does not appear to be additive. Ergogenic effects
of the combination of these substances on running per-
formance have not yet been supported [7].
Whitehead et al. [12] assigned men to a placebo (n = 13)
or a proprietary-blend supplement (Jack3d®;n = 12) condi-
tion, where subjects were directed to consume their
assigned supplement on training days for the course of
10 weeks. No condition differences were noted for blood
pressure, heart rate, or any variable of blood borne
markers of health. Another sample of men (n = 7) con-
sumed Jack3d®, while men (n = 4) and women (n = 2)
consumed a different proprietary-blend supplement
(OxyELITE Pro®) for two weeks [9]. In this open-label
design, no significant chronic changes in heart rate,
blood pressure, or rate pressure product noted for
either product, although OxyELITE Pro® acutely in-
creased systolic blood pressure. Since both of these
products contain unique additional substances, it is dif-
ficult to ascribe responses to DMAA.
Finally, two studies examined OxyELITE Pro® in both
acute [10] and chronic [11] conditions. Acutely, the sup-
plement caused a significantly greater area under the
curve for glycerol, free fatty acids, and kcal expenditure
at rest. Heart rate, systolic blood pressure and rate pres-
sure product were also higher with the supplement than
the placebo [10]. Eight weeks of supplementation with
the supplement or placebo did not demonstrate interac-
tions for body weight, body composition, skinfold thick-
ness, serum lipids or appetite [11].
To conclude on the safety profile of DMAA based
solely on case reports would be problematic, in particu-
lar when accepting testimony from patients in uncon-
trolled environment, potentially under the influence of
alcohol and other drugs. This is especially true in light
of the fact that no prospective studies have shown these
effects. Hence, the intent of the present study was to de-
termine the pharmacokinetic profile of a single 25 mg
oral dosage of DMAA alone through 24 hours post-
ingestion. The results of this study, along with current
available information, may provide a more comprehen-
sive view of the effects of oral administration of this in-
gredient in humans.
Methods
Subjects and data collection
Eight healthy men (26 ± 4.1 y) were recruited to partici-
pate. Subjects met inclusion criteria by not currently
smoking, and they did not have any self-reported cardio-
vascular or metabolic problems. Men were recruited so
that there would be no possible gender effects, and since
little is known about this ingredient, we thought it pru-
dent to reduce potential confounding factors. Health his-
tory, drug and dietary supplement usage, and physical
activity questionnaires were completed by all subjects
and screened by an investigator to determine eligibility.
Prior to participation, each subject gave written and ver-
bal informed consent for procedures and publication of
data in accordance with the procedures approved by the
University of Memphis Institutional Review Board for
Human Subjects Research (protocol approval number
2102). This trial is registered as NCT01765933. After
giving informed consent, subjects had a dual x-ray ab-
sorptiometry (DXA) scan (Hologic QDR 4500, Bedford,
MA) to measure fat mass and lean mass for descriptive
purposes.
Subjects reported to the lab in the morning following
an 8-hour overnight fast to minimize the possible effects
of stomach contents. This is also similar to the instruc-
tions on some supplement labels. Subjects were asked to
abstain from any dietary supplement containing DMAA
for 72 hours prior to testing and also asked to refrain
from strenuous physical activity for the 36 hours prior
to testing. Following the measurement of resting heart
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rate (via 60 second palpation), blood pressure (standard
manual procedures), and cutaneous temperature (fore-
head), in addition to collection of a fasting blood sample
(as described below), subjects received 25 mg of DMAA
in a cellulose capsule supplied by USPlabs (Dallas, TX).
These are similar to capsules previously available com-
mercially. The DMAA capsules used in this study were
submitted for analysis to confirm the 25 mg dose. Mean
concentration (±SD) of 10 capsules randomly selected
from the same lot as the study capsules was 23.9 ±
1.9 mg. Subsequent measures of heart rate, blood pres-
sure, and cutaneous temperature were obtained, and
blood samples were taken at intervals over a 24 hour
period (0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and
24 hr). Heart rate, blood pressure, and cutaneous
temperature data were obtained to note the time effect
on these variables [13]. Subjects remained in the lab for
the first 8 hours of testing. They were given standardized
meals for the 24- hour testing period (meals were con-
sumed immediately after 3 and 6-hour draws, between 8
and 12-hour draws, and between 12 and 16 hours post-
DMAA ingestion). They were instructed to have min-
imal physical activity, and return to the lab 8-hours
fasted at the time of the 24-hour blood draw.
Blood collection and processing
Peripheral IV catheters (straight, 22 ga., length: 1” poly-
urethane) were inserted and secured prior to first blood
draw and monitored throughout the first eight hours.
The IV site was immediately covered with a transparent
dressing to decrease the chance of infection and to allow
for catheter monitoring. Venous blood samples (approxi-
mately 5 mL) were taken from subjects at intervals as
described above. The first 0.5-1 mL of each sample was
discarded to avoid contamination, the sample was col-
lected, and the catheter was flushed with 2–3 ml of 0.9%
saline solution. Blood samples at 12 and 24 hr were
performed with standard needle venipuncture. Following
collection, blood samples were processed accordingly
with sodium heparin and plasma samples were stored at
−70°C until analyzed.
Plasma DMAA analysis
Plasma samples from the subjects were screened with
high-performance liquid chromatography–mass spectrom-
etry (an Agilent 1200 series HPLC [Agilent Technologies,
Santa Clara, CA] with an ABSciex 3200 QTrap mass
spectrometer [AB-Sciex, Foster City, CA]). Based on
the properties of both DMAA and human plasma, we
DMAA=20 ppb
Time
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
050512-47 MRM of 1 Channel ES+ 
TIC
3.63e4
9.65
8.26
8.56
Figure 1 Chromatogram of samples spiked at 20 ng/mL DMAA= 8.26 min and 8.56 min; 9.65 min = 2-aminoheptane.
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combined TCA precipitation with LC-MS-MS using
analysis of DMAA in urine as reference [14,15], and 2-
aminoheptane as an internal standard. In this method,
the lower limit of quantitation (LLOQ) was estimated
based on the lowest level in standard curve (R2 > 0.99)
(instrument sensitivity) and sample preparation. We fore-
casted that 5–50 ng/ml would cover the range of blood
DMAA levels; therefore, we set up the accuracy experi-
ment within 5–50 ng/ml-spiked levels. The LLOQ was 1–
2 ng/ml (1 ng∙mL-1 average), and the average recovery
was 92.4-97.4% when samples were spiked between 5–
50 ng/ml; CV 0.9-6.8% between 5–50 ng/ml. Represen-
tative chromatograms are shown in Figures 1, 2 and 3.
There is a double chromatographic peak of the racemic
mixture that is made and sold commercially [14,15].
Pharmacokinetic analysis
DMAA plasma concentration-time data were evaluated
using noncompartmental analysis in Phoenix WinNonlin
software with adjustment for lag time after oral adminis-
tration. The area under the plasma concentration-time
curve from time 0 to infinity (AUC0-∞) was calculated
using the trapezoidal rule extrapolated to time infinity.
The terminal half-life (t 1/2) was calculated using 0.693/
λz, with λz as the terminal rate elimination constant.
Peak concentration (Cmax), lag time (tlag), time of max-
imum concentration (tmax), apparent volume of distribu-
tion during the terminal elimination phase (Vz/F), and
oral clearance (CL/F) were also calculated.
Statistical analysis
Physiological response data (heart rate, blood pressure,
temperature) were analyzed using a one-way repeated
measures analysis of variance. The data are presented as
mean ± SD. Statistical significance was set at P ≤ 0.05, with
Sidak post-hoc adjustments for multiple comparisons.
Effect sizes were also calculated for selected pairwise com-
parisons, with corrections for correlations in repeated
measures, and interpretation according to Hopkins [16].
Results
One participant had extremely high blood levels of
DMAA, including a high baseline value of 131.1 ng∙mL-1
and a Cmax of 266.2 ng∙mL
-1 occurring at 24 hours. As
H1 
Time
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
050512-52 MRM of 1 Channel ES+ 
TIC
2.52e4
9.55
8.15
2.97
Figure 2 Chromatogram for subject #8 at baseline; 1.5 ng/ml DMAA.
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the participant had rising blood levels throughout the
experimental window, it was impossible to calculate a
terminal half-life. Upon questioning, the subject denied
taking a DMAA product within 72 hours of testing, so
the reason for/source of the high levels is unknown and
could not be attributed to a specific methodological
issue. The physiological variables for this subject were
comparable to the other participants, but the subject’s
DMAA tmax and Cmax increased mean pharmacokinetic
values by roughly 70% and 30%, respectively. Therefore,
all data from the subject were excluded from the ana-
lysis. Subject characteristics for the seven subjects are
presented in Table 1.
Physiological data
A significant time effect was observed for heart rate
(p < 0.000; Figure 4), but no significant pairwise differ-
ences were noted. It should be noted that heart rate was
slightly elevated at 12 hours post-ingestion (69.1 ± 2.9
BPM) compared to baseline (61.0 ± 3.2 BPM), with a large
effect size of 1.9. A significant time effect (p = 0.001) was
observed for temperature (Figure 5), with values
significantly elevated 12-hours post-ingestion when
compared to two hours (p = 0.025, ES = 4.3) and three
hours (p = 0.009, ES = 3.4). No changes were seen over
time for blood pressure (Figure 6). Systolic blood pres-
sure exhibited a moderate-to-large effect size (0.9)
when comparing values at 24 hours post-ingestion
(115 ± 3 mm Hg) vs. pre-ingestion (118 ± 3 mm Hg).
There was a moderate effect size (0.5) when comparing
diastolic blood pressure values at baseline (77 ± 4.4 mmHg)
and at 0.25 hr post-ingestion (82 ± 3 mm Hg).
Pharmacokinetic data
Each subjects’ pharmacokinetic parameters are shown
in Table 2. Values for plasma DMAA of subjects peaked
H4
Time
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
%
0
100
050512-55 MRM of 1 Channel ES+ 
TIC
2.54e4
9.55
8.22
3.02
8.50
Figure 3 Chromatogram for subject #8 at 0.75 hrs post ingestion; 44 ng/ml DMAA.
Table 1 Participant descriptive information (n = 7)
Age (y) Lean body
mass (kg)
Fat mass (kg) Total body
mass (kg)
% Fat
Mean 26.7 68.1 11.2 79.3 13.9
SD 4.3 6.0 4.9 8.3 4.8
Range 23-36 58.7-75.8 6.1-21.4 68.7-92.8 8.2-23.1
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at approximately 70 ng∙mL-1. The oral clearance was
20.02 ± 5 L∙hr-1, the oral volume of distribution was
236 ± 38 L, and terminal half-life was 8.45 ± 1.9 hr. Lag
time varied among participants but averaged approxi-
mately 8 minutes (0.14 ± 0.13 hr). Individual and mean
DMAA plasma-concentration time profiles are shown
in Figure 7.
Discussion
The most important finding in this investigation is the
relatively low plasma concentrations of DMAA corre-
sponding to the 25 mg oral dose, and the lack of mean-
ingful physiologic effects associated with the single dose.
Since data from a standardized and verified dose of
DMAA was not previously available, our findings shed
light on the possible reason for the adverse outcomes
noted in prior case reports citing DMAA use (i.e., highly
abusive dosages of this ingredient) [5,6]. Our data show
a consistent pattern of increase across subjects with
regards to peak plasma DMAA concentration, with peak
values approximately 15–30 times lower than those
reported in the case studies—strongly questioning the
accuracy of reporting by patients in the case reports
[5,6]. It is hypothesized that patients in the case reports
may have ingested dosages of DMAA that were approxi-
mately 15–30 times higher than what our subjects
ingested (i.e., 375 mg-750 mg). In fact, based on the time
course of our peak response data (~5 hours post-
ingestion), coupled with the times provided by Gee et al.
[5,6] for blood sample collection from their patients (i.e.,
before or after our noted peak concentration time), it is
possible that our “15-30 times higher” estimation is quite
low. The conclusions from our data are based on the as-
sumption of linearity of DMAA PK, and that no previ-
ous DMAA was ingested by the participants. Also, no
assumption of linearity can be made from our data since
only one dose was used. The information regarding
DMAA dosage as reported by patients in the work of
Gee et al. [5,6] is not supported by our controlled la-
boratory analysis involving plasma sample analysis. If
Figure 4 Heart rate responses (BPM) after oral administration of 25 mg DMAA (n = 7). Data are mean ± SD. A significant time effect was
noted (p < 0.000), but no pairwise differences were detected post-hoc (p > 0.05).
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these patients did in fact ingest such high dosages of
DMAA (as directly indicated in the earlier report of Gee
and coworkers, where the subject reportedly ingested
556 mg of DMAA) [6], it should not be surprising that
such a blatant abuse resulted in untoward effects. This is
particularly true when considering that these patients
may have been using other chemicals along with the
DMAA (e.g., alcohol, caffeine, phenethylamine, canna-
bis). Indeed, the ingestion of other “stimulant-like” sub-
stances such as caffeine at a similarly high concentration
taken as one dosage (e.g., 2250 mg-4500 mg; assuming a
typical intake of 150 mg) could be highly problematic.
The abnormal response of the one subject in our study
cannot be readily explained. This subject did say that he
was lightheaded immediately after the catheter place-
ment, but this quickly subsided and was not present at
the time of the DMAA administration. Since the subject
denied taking DMAA within the 72-hour window pre-
ceding the experiment, it remains unclear why these
values were so different from the other participants.
Compared to the commonly available stimulant caf-
feine, DMAA has a longer t1/2, in this case 8.4 h vs.
5.4 hr for caffeine [17], as well as a shorter lag time of
0.14 h vs. 0.37 h for caffeine [17]. Previous reports have
indicated that DMAA is absorbed over 4–12 hours [13].
It should be noted that caffeine also has interactive ef-
fects with oral contraceptives (increasing t1/2) and other
simultaneously ingested stimulants [17]. Examining the
pharmacokinetics of combined DMAA/caffeine inges-
tion (as is commonly available in supplement formula-
tions) could provide interesting data.
While a significant increase in temperature at 12-
hours post-ingestion is noted in our data, the values are
still within normal range of 36.1 to 37.8°C, suggesting
little meaningful effect is present. The increase in
temperature is likely attributable to the fact that subjects
were out of the lab and reported back for testing, and
that activity associated with leaving and returning to the
lab slightly elevated temperature. These data are import-
ant to ensure that reports in the lay media of those
Figure 5 Blood pressure responses (mm Hg) after oral administration of 25 mg DMAA (n = 7). Data are mean ± SD. No significant time
effects noted (p = 0.271 for diastolic blood pressure and p = 0.722 for systolic blood pressure).
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reportedly taking DMAA suffering heat injury [18] can
be contextualized. Further study of DMAA effects on
temperature in the context of exercise and heat exposure
is warranted.
Even with the significant time effect for heart rate, the
grand mean was 64 bpm and the range was 50–88 bpm,
well within normal clinical values for healthy young
men. Farney et al. [9] noted maximum increases of
about 7 bpm 90 minutes after ingestion of OxyELITE
Pro® (a supplement containing DMAA along with several
other ingredients), which is more than the 3 bpm change
we noted at the same time period after ingestion of
Figure 6 Temperature (°F) after oral administration of 25 mg DMAA (n = 7). There was a significant time effect (p = 0.001) noted.
* indicates 12-hour greater than 2 hr (p = 0.025). † indicates 12-hour greater than 3-hr (p = 0.009). Data are mean ± SD.
Table 2 Individual pharmacokinetic parameters after oral administration of 25 mg DMAA (n = 7)
Subject t1/2 (hr) tlag (hr) tmax (hr) Cmax (ng∙mL
-1) AUC0-∞ (hr ng∙mL
-1) Vz/F (L) Cl/F (L∙hr
-1)
2 7.84 0.0 2.5 82.85 1281.88 203.04 17.94
3 6.92 0.25 5.0 108.1 893.23 257.13 25.75
4 6.57 0.25 6.0 60.23 1136.17 191.87 20.24
5 7.13 0.25 2.0 63.14 818.91 289.05 28.09
6 9.29 0.0 4.0 76.68 1456.19 211.73 15.79
7 11.79 0.25 3.0 68.07 1420.82 275.29 16.19
8 9.660 0.0 2.5 76.69 1424.23 223.55 16.15
Mean 8.449 0.143 3.57 76.54 1204.550 235.95 20.02
SD 1.87788 0.134 1.48 16.09 262.89 37.82 5.00
%CV 22.22 93.71 41.46 21.02 21.83 16.03 24.96
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DMAA alone. Our heart rate data are more similar to
McCarthy et al. [10], showing an increase of 4 bpm at
120 minutes post-ingestion of Jack3d® (another supple-
ment containing DMAA along with other ingredients).
It should be noted that McCarthy et al. [10] demon-
strated an increase of about 4 bpm at 120 min post-
ingestion of OxyELITE Pro®, similar to Farney et al. [9].
Our data are perhaps best compared with those of
Bloomer et al. [8] who actually noted a decrease in heart
rate of about 4 bpm and 3 bpm with ingestion of 50 mg
and 75 mg of DMAA alone, respectively. Since all of
these values are within normal ranges, it appears the ef-
fects of DMAA on heart rate are indeed minimal.
The lack of time effects for blood pressure is not sur-
prising, and these values are within normal clinical
ranges and well below values for hypertension. The sys-
tolic blood pressure grand mean was 118 mm Hg, with a
range of 96–130 mm Hg. The diastolic blood pressure
grand mean was 78 mm Hg, ranging from 60–88 mm
Hg. Farney et al. [9] noted a significant increase in sys-
tolic blood pressure at 60, 90, and 120 post-ingestion of
OxyELITE Pro®, but not Jack3d®. However, their max-
imum values were very similar for the two substances,
and all of their values are similar to ours, aside from the
greater baseline values for our study. McCarthy et al.
[10] also had a significant time effect for OxyELITE Pro®
on systolic blood pressure, and again their maximum
values are similar to those herein. Study of non-
proprietary concentrations of DMAA [8] demonstrated
somewhat greater blood pressure effects for 50 and
75 mg (~8 and 12 mm Hg) than we noted for our 25 mg
dose. Of the aforementioned studies, only Bloomer et al.
[8] reported a significant increase in diastolic blood
pressure, at both 50 and 75 mg doses, and at time points
30, 60, and 90 minutes post-ingestion.
Conclusions
We report for the first time the pharmacokinetic profile
of oral DMAA. Based on our data, it appears that the
concern over adverse health-related effects of DMAA is
specific to the dosage ingested by the individual. When
ingested at recommended doses (e.g., 25 mg), our data
indicate minimal to no change in heart rate, blood pres-
sure, or body temperature, and no adverse effects were
noted. We also note a consistent pattern of increase
across subjects concerning peak DMAA concentration,
with mean peak values being <77 ng∙mL-1. This is ap-
proximately 15–30 times lower than plasma values
reported by other investigators citing adverse outcomes
following DMAA use. However, due to the case-study
format of some of these adverse events, one cannot ig-
nore possible drug interaction, errors in bioanalytical
methods, differing bioavailability, or variability in expos-
ure that might make this comparison difficult. Interpret-
ation of our data would lead one to hypothesize that the
adverse outcomes associated with DMAA use are simply
due to the blatant abuse of this ingredient. Future research
on DMAA may consider pharmacokinetic characterization
of each individual diastereoisomer [14,15].
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Figure 7 Individual and mean plasma concentration-time profiles after oral administration of 25 mg DMAA.
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